Tamar D. Howson - 03 Jan 2023 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship: Director
Issuer ticker: CUE
Reported as of: 03 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2023, 15:09:28 UTC
Prior SEC filing: 07 Jul 2022
Next SEC filing: 29 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Tamar Howson by Colin Sandercock, attorney-in-fact

Key filing fact

Tamar D. Howson filed Form 4 for Cue Biopharma, Inc. (CUE) on 05 Jan 2023.

Key facts

This page summarizes Tamar D. Howson's Form 4 filing for Cue Biopharma, Inc. (CUE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2023, 15:09.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CUE transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 2 footnotes

Footnote F1

Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

Footnote F2

This option was granted on January 3, 2023. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date.